Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.
A PDUFA target date of November 24, 2022 has been set for the application.
Patient age, treatment center, and tumor size were associated with a lack of adherence.